Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently unapproved by the MHRA, EMA, or FDA for routine clinical use
This information is intended as a guide only, including because products change from time to time
It is important to note that all scientifically verified effects described below are based on preclinical research, including in vivo rodent models and in vitro cellular systems
Research suggests that this peptide helps block the transformation of non-fatty foods into body fat, making it harder for the body to store new weight
Use 5,000 mcg daily of sublingual methylcobalamin, taken in the morning away from thyroid medication